Physician profile
David Kuo
NPI 1508881640
$7,959.67
in general payments reported to CMS, 2019-2025
51 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $773 · 2021: $1,006 · 2022: $1,392 · 2023: $1,221 · 2024: $914 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $802.53 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Lilly USA, LLC | $757.00 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.46 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $586.53 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $355.63 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $326.80 | 2019-2023 | |
| Abbott Laboratories | $308.61 | 2020-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $303.99 | 2020-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $284.23 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $276.36 | 2021-2025 | Gvoke Hypopen |
| Allergan, INC. | $261.01 | 2019-2020 | |
| Gilead Sciences, INC. | $248.78 | 2019-2023 | |
| Viiv Healthcare Company | $220.85 | 2019-2025 | Apretude |
| Astrazeneca Pharmaceuticals LP | $220.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $218.89 | 2019-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $192.18 | 2019-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $155.73 | 2022-2024 | |
| Pfizer INC. | $143.28 | 2019-2025 | |
| Novo Nordisk INC | $142.58 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $127.16 | 2021-2025 | Dexcom G6 Transmitter |
| Insmed, INC. | $120.86 | 2019-2023 | Arikayce |
| Medtronic, INC. | $93.00 | 2021-2025 | Minimed 780g |
| Paratek Pharmaceuticals, INC. | $76.81 | 2022-2025 | Nuzyra |
| Amarin Pharma, INC. | $76.10 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $70.46 | 2019 | |
| Janssen Biotech, INC. | $70.27 | 2019-2023 | Symtuza |
| Lifescan, INC. | $70.16 | 2020-2022 | |
| Sanofi Pasteur INC. | $69.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.97 | 2019-2025 | Eliquis |
| Ascensia Diabetes Care US INC. | $60.00 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $51.09 | 2021 | |
| Edwards Lifesciences Corporation | $45.97 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $45.44 | 2019-2024 | Watchman Flx |
| Daiichi Sankyo INC. | $42.61 | 2021 | |
| Kyowa Kirin, INC. | $38.86 | 2023-2024 | Crysvita |
| Tetraphase Pharmaceuticals, INC. | $37.82 | 2020 | |
| Mylan Specialty L.P. | $35.51 | 2019 | |
| Lucid Diagnostics INC. | $27.11 | 2022 | |
| Esperion Therapeutics, INC. | $23.18 | 2021 | |
| Sequel Med Tech, LLC | $20.51 | 2025 | Twiist |
| Actelion Pharmaceuticals US, INC. | $19.72 | 2024 | Opsumit |
| Tandem Diabetes Care, INC. | $18.85 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2022 | |
| Mannkind Corporation | $16.61 | 2021 | |
| Inspire Medical Systems, INC. | $15.09 | 2024 | Inspire |
| Antares Pharma, INC. | $14.52 | 2019 | |
| Cequr Corporation | $14.37 | 2025 | Cequr Simplicity |
| Qiagen, LLC | $13.64 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.20 | 2021 | |
| Melinta Therapeutics, LLC | $12.99 | 2020 | |
| Exact Sciences Corporation | $12.92 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.